Ftse Mib
35.398,82
-0,03%
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
NASDAQ
16.685,97
-0,07%
Bitcoin
67.005,55
-0,11%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Bellicum Pharmaceuticals Inc (BLCM) Bellicum Pharmaceuticals Inc (BLCM) Notizie

BLCM

Bellicum Pharmaceuticals (BLCM)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BLCM
DataOraFonteTitoloSimboloCompagnia
23/02/202419:19Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:BLCMBellicum Pharmaceuticals Inc
23/02/202419:17Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:BLCMBellicum Pharmaceuticals Inc
15/02/202400:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BLCMBellicum Pharmaceuticals Inc
30/01/202422:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BLCMBellicum Pharmaceuticals Inc
30/05/202322:13Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/05/202322:24Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:BLCMBellicum Pharmaceuticals Inc
05/05/202322:05Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:BLCMBellicum Pharmaceuticals Inc
31/03/202322:08Edgar (US Regulatory)Annual Report (10-k)NASDAQ:BLCMBellicum Pharmaceuticals Inc
14/03/202321:30GlobeNewswire Inc.Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic AlternativesNASDAQ:BLCMBellicum Pharmaceuticals Inc
16/02/202313:30GlobeNewswire Inc.Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers SymposiumNASDAQ:BLCMBellicum Pharmaceuticals Inc
14/02/202318:07Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
01/02/202300:43GlobeNewswire Inc.CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
31/01/202322:36GlobeNewswire Inc.Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
20/01/202320:26Edgar (US Regulatory)Amended Statement of Changes in Beneficial Ownership (4/a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
19/01/202313:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers SymposiumNASDAQ:BLCMBellicum Pharmaceuticals Inc
05/01/202319:14Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/12/202216:00GlobeNewswire Inc.Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with RimiducidNASDAQ:BLCMBellicum Pharmaceuticals Inc
18/11/202221:02Edgar (US Regulatory)Statement of Beneficial Ownership (sc 13d)NASDAQ:BLCMBellicum Pharmaceuticals Inc
10/11/202222:05GlobeNewswire Inc.Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
24/10/202222:17Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
14/10/202222:23Edgar (US Regulatory)Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
04/10/202213:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the MesaNASDAQ:BLCMBellicum Pharmaceuticals Inc
01/09/202213:30GlobeNewswire Inc.Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment ConferenceNASDAQ:BLCMBellicum Pharmaceuticals Inc
11/08/202222:14Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:BLCMBellicum Pharmaceuticals Inc
11/08/202222:02GlobeNewswire Inc.Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
24/05/202212:09Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:BLCMBellicum Pharmaceuticals Inc
13/05/202222:15Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:BLCMBellicum Pharmaceuticals Inc
12/05/202222:05GlobeNewswire Inc.Bellicum Reports First Quarter 2022 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
29/04/202222:35Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:BLCMBellicum Pharmaceuticals Inc
24/03/202221:05GlobeNewswire Inc.Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational UpdateNASDAQ:BLCMBellicum Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:BLCM

La tua Cronologia

BIT
I09808
IT0005574410 20240920 22...
NYSE
BCSF
Bain Capital Specialty F...
NASDAQ
AAXQQXX
JPMorgan Chase Financial...
NYSE
ZEV
Lightning eMotors
EU
ALDAG
ALD SA Preferred Mtn 4.3...
BIT
S29784
Societe Generale Effekten
LSE
ULBS
Qnb Fin 25
BITMOT
900478
Wiit Tf 2,375% Ot26 Call...
LSE
IQ24
Citi Fun 26
NASDAQ
ABAZAXX
Morgan Stanley Bank Na A...
LATK
CPCBTC
CPChain
EU
BER0000454P6
Record Record 1.2% 10y 1...
NASDAQ
XCRA
Xcerra Corp
LSE
SFX
Screen Fx
NASDAQ
BOVA
Bank OF Virginia
LSE
PP47
Citi Fun 25
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network